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Abstract
Gastrointestinal feeding intolerance and critical illness-associated gastric motility dysfunction are common. Although
recent guidelines recommend not interrupting gastric feeding when gastric residual volume (GRV) is lower than
500 mL or to completely abandon measurement of GRV, it may seem that the relevance of prokinetics is reduced.
In patients at risk for aspiration and in multimodal strategies to enhance feeding performance, however, use of
prokinetics is still advocated. Metoclopramide and erythromycin are commonly used promotility agents, although
with relevant side effects.
Potential targets for new agents and early study results are addressed.
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Commentary
A clear consensus definition on acute gastrointestinal in-
jury during critical illness is lacking. Gastrointestinal
feeding intolerance (GFI) is usually defined by vomiting,
abdominal distention, complaints of discomfort, high
nasogastric tube output, high gastric residual volumes
(GRVs) measured at intervals, diarrhea, reduced passage
of flatus and stool, or abnormal abdominal radiographs
[1]. In daily practice, ICU nurses typically assess intoler-
ance solely by measuring GRVs, with common threshold
levels for interrupting enteral nutrition (EN) ranging
from 200–250 mL [2]. GFI may be encountered in 50 %
of ventilated patients, depending on the diagnosis, pre-
morbid condition, ventilation mode, medications, and
metabolic state [3].
The recently updated guidelines for adult critically ill
patients by the Society of Critical Care Medicine (SCCM)
and American Society for Parenteral and Enteral Nutrition
(ASPEN) suggest that, in most patients, it is acceptable to
initiate EN in the stomach. Patients should be monitored
daily for tolerance of EN and inappropriate cessation of
EN should be avoided. Administration should be diverted
lower in the gastrointestinal tract (post-pyloric feeding) in
patients at high risk for aspiration or in case of gastric EN
intolerance [4].
Now here a clinical dilemma may arise: The most
likely routine to monitor GFI is to measure GRV. How-
ever, GRVs do not correlate with incidences of pneumo-
nia, regurgitation, or aspiration. GRVs were shown to
have very low sensitivity and positive and negative pre-
dictive value to predict aspiration [4]. Raising the cutoff
value for GRVs (to interrupt EN administration) from
50–150 to 250–500 mL does not increase the incidence
of complications. Moreover, recent studies have sug-
gested that it is safe to completely abandon measuring
GRV and as a consequence nutritional targets are better
achieved, although more vomiting was noticed in one
study [5, 6].
Combining evidence and pragmatism ASPEN/SCCM
recommends GRVs not be used as part of routine care
to monitor ICU patients receiving EN. However, for
those ICUs where GRVs are still utilized, holding EN forCorrespondence: zantena@zgv.nl
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GRVs <500 mL in the absence of other signs of intolerance
should be avoided [4].
Should we then also abandon use of prokinetics to im-
prove feeding performance in case gastric emptying is
reduced as reflected by increased GRVs? Probably not.
For patients at risk for aspiration it is recommended
to initiate promotility agents, such as metoclopramide
and erythromycin, where clinically feasible [4]. However,
risk factors are present in almost all ICU patients [7].
Moreover protocols applying volume-based feeding in
conjunction with prokinetics from the initiation of feed-
ing and that only stop administration of these promoti-
lity agents if no longer required have been shown to
increase EN delivery while reducing the incidence of
nosocomial infections compared with ICUs without such
protocols [8, 9].
The most commonly used prokinetics are metoclopra-
mide and erythromycin. Erythromycin use has been
associated with cardiac toxicity, tachyphylaxis, and bac-
terial resistance [10]. Adverse complications of metoclo-
pramide include tardive dyskinesia, akathisia related to
the rate of infusion, and various cardiovascular side ef-
fects, although reported adverse events in critically ill
patients are rare [11].
Both agents may confer QT prolongation, predisposing
to cardiac arrhythmias. Another problem of prokinetics
is the occurrence of tachyphylaxis, the phenomenon
that treatments become less effective during prolonged
administration [11].
Critical illness-associated gastric motility dysfunction
is multifactorial and predominantly comprises antral
hypomotility, delayed gastric emptying, and reduced mi-
grating motor complexes [12]. Gastric smooth muscle is
activated by acetylcholine. In general, neurons that secrete
acetylcholine are excitatory, enhance smooth muscle con-
traction, increase intestinal secretions, release enteric hor-
mones, and dilate blood vessels. In a complex interplay of
vagal tone and receptor activation or antagonism of insu-
lin, glucagon, serotonin, dopamine, motilin, cholecysto-
kinin, peptide YY, and ghrelin, among other factors,
gastric emptying is regulated. During critical illness this
regulation is disrupted and the gastric emptying rate is re-
duced. Several drug targets have been identified to develop
new promotility agents (Fig. 1) and several new medica-
tions are under investigation [13].
In a recent systematic review and meta-analysis of 13
randomized controlled trials comparing prokinetics with
placebo, Lewis and coworkers demonstrated that there is
moderate-quality evidence that prokinetic agents reduce
feeding intolerance in critically ill patients compared
with placebo or no intervention [14]. They furthermore
concluded that the impact on other clinical outcomes
such as pneumonia, mortality, and ICU length of stay
is unclear. Therefore, we need new highly effective
Fig. 1 Potential pharmacological targets to treat critical illness-associated gastric motility dysfunction. During critical illness availability of
acetylcholine to stimulate gastric smooth muscle is lower due to modulation of vagal tone and reduced levels of serotonin, motilin, and
ghrelin resulting in reduced gastric emptying rate. Drugs that increase acetylcholine availability and receptor agonists of these (enteric)
hormones may have potential prokinetic activity. Selective receptor blockers of opioids (in case of opioid use) and cholecystokinin or dopamine are
other potential promotility agents
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prokinetics with limited or absent tachyphylaxis and no
serious side effects.
Recently in Critical Care Chapman and coworkers re-
ported that camicinal (GSK962040), a novel motilin agon-
ist, at present only available for enteral administration,
accelerates gastric emptying in feed-intolerant critically ill
patients compared with placebo, resulting in augmented
glucose absorption and improved gastric emptying [15].
Glucose absorption increased two-fold following adminis-
tration of 50 mg of camicinal. This is important as the ul-
timate goal is not only to prevent complications of gastric
feeding but, more importantly, to improve feeding per-
formance reflected by a better absorption of nutrients.
Although the small sample size (15 camicinal patients
versus eight placebo patients), no detectable plasma
levels in two patients—an observation difficult to under-
stand—and no comparison with the commonly used
prokinetics metoclopramide and erythromycin are study
limitations, results are promising as no safety issues were
detected, such as QTc-interval prolongation. Due to the
study design, information on tachyphylaxis is still lacking.
Several other studies in critically ill patients addressing
the performance of novel prokinetics are ongoing or are
soon to commence in international study sites (PRO-
MOTE Trial studying the efficacy of the ghrelin agonist
ulimorelin versus metoclopramide (NCT02784392) and
the NUTRIATE Study comparing camicinal (GSK962040)
50 mg versus metoclopramide (NCT01934192).
Until robust study results in critically ill patients com-
paring new prokinetic agents with commonly used pro-
kinetics have shown the safety and efficacy of these new
promotility agents, we still have to rely on metoclopra-
mide and erythromycin as prokinetics to improve feed-
ing performance in patients at high risk for aspiration
and critical illness-associated gastric motility dysfunction
while closely monitoring side effects.
However, motility research is moving rapidly towards
new therapeutic options to improve our pharmacological
armamentarium for critical illness-associated gastric mo-
tility dysfunction.
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